Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing | Cancer Biomarkers | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Bianchi  DW, Wilkins-Haug  L.  Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road?  Clin Chem. 2014;60(1):78-87.PubMedGoogle ScholarCrossref
Lau  TK, Jiang  FM, Stevenson  RJ,  et al.  Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service.  Prenat Diagn. 2013;33(6):602-608.PubMedGoogle ScholarCrossref
Bayindir  B, Dehaspe  L, Brison  N,  et al.  Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management.  Eur J Hum Genet. 2015.PubMedGoogle Scholar
Heitzer  E, Ulz  P, Belic  J,  et al.  Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.  Genome Med. 2013;5(4):30.PubMedGoogle ScholarCrossref
Chan  KC, Jiang  P, Zheng  YW,  et al.  Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.  Clin Chem. 2013;59(1):211-224.PubMedGoogle ScholarCrossref
Bettegowda  C, Sausen  M, Leary  RJ,  et al.  Detection of circulating tumor DNA in early- and late-stage human malignancies.  Sci Transl Med. 2014;6(224):224ra24.PubMedGoogle ScholarCrossref
Vandenberghe  P, Wlodarska  I, Tousseyn  T,  et al.  Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.  Lancet Haematol. 2014;2(2):e55-e65.Google ScholarCrossref
Osborne  CM, Hardisty  E, Devers  P,  et al.  Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease.  Prenat Diagn. 2013;33(6):609-611.PubMedGoogle ScholarCrossref
McCullough  RM, Almasri  EA, Guan  X,  et al.  Non-invasive prenatal chromosomal aneuploidy testing—clinical experience: 100,000 clinical samples.  PLoS One. 2014;9(10):e109173.PubMedGoogle ScholarCrossref
National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER).  SEER Cancer Statistics Fact Sheets: Non-Hodgkin Lymphoma. Bethesda, MD: National Cancer Institute; 2015.
Ferlay  J, Soerjomataram  I, Dikshit  R,  et al.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.  Int J Cancer. 2015;136(5):E359-E386.PubMedGoogle ScholarCrossref
Brenner  B, Avivi  I, Lishner  M.  Haematological cancers in pregnancy.  Lancet. 2012;379(9815):580-587.PubMedGoogle ScholarCrossref
Amant  F, Van Calsteren  K, Halaska  MJ,  et al.  Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study.  Lancet Oncol. 2012;13(3):256-264.PubMedGoogle ScholarCrossref
Amant  F, von Minckwitz  G, Han  SN,  et al.  Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.  J Clin Oncol. 2013;31(20):2532-2539.PubMedGoogle ScholarCrossref
Han  SN, Verheecke  M, Vandenbroucke  T, Gziri  MM, Van Calsteren  K, Amant  F.  Management of gynecological cancers during pregnancy.  Curr Oncol Rep. 2014;16(12):415.PubMedGoogle ScholarCrossref
Brief Report
September 2015

Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing

Author Affiliations
  • 1Department of Obstetrics and Gynecology, Gynecological Oncology, Katholieke Universiteit (KU) Leuven–University of Leuven, University Hospitals, Leuven, Belgium
  • 2Center for Human Genetics, KU Leuven–University of Leuven, University Hospitals Leuven, Belgium
  • 3Department of Hematology, KU Leuven–University of Leuven, University Hospitals, Leuven, Belgium
  • 4Department of Radiology, KU Leuven–University of Leuven, Leuven, Flanders, Belgium
  • 5Department of Pathology, Translational Cell and Tissue Research, KU Leuven–University of Leuven, Leuven, Belgium
  • 6Department of Obstetrics and Gynecology, Gynecologic Oncology, University Hospital, Leuven–General Hospital, Sint-Maarten Duffel, Belgium
  • 7Department of Obstetrics and Gynecology, General Hospital H. Hart, Leuven, Belgium
  • 8Department of Obstetrics and Gynecology, General Hospital Delta, Roeselare, Belgium
JAMA Oncol. 2015;1(6):814-819. doi:10.1001/jamaoncol.2015.1883

Importance  Noninvasive prenatal testing (NIPT) for fetal aneuploidy by scanning cell-free fetal DNA in maternal plasma is rapidly becoming a major prenatal genetic test. Similar to placental DNA, tumor DNA can be detected in the plasma, and analysis of cell-free tumor DNA can be used to characterize and monitor cancers. We show that plasma DNA profiling allows for presymptomatic detection of tumors in pregnant women undergoing routine NIPT.

Observations  During NIPT in over 4000 prospective pregnancies by parallel sequencing of maternal plasma cell-free DNA, 3 aberrant genome representation (GR) profiles were observed that could not be attributed to the maternal or fetal genomic constitution. A maternal cancer was suspected, and those 3 patients were referred for whole-body diffusion-weighted magnetic resonance imaging, which uncovered an ovarian carcinoma, a follicular lymphoma, and a Hodgkin lymphoma, each confirmed by subsequent pathologic and genetic investigations. The copy number variations in the subsequent tumor biopsies were concordant with the NIPT plasma GR profiles.

Conclusions and Relevance  We show that maternal plasma cell-free DNA sequencing for noninvasive prenatal testing also may enable accurate presymptomatic detection of maternal tumors and treatment during pregnancy.